MedDataX Logo

Effect of D-allulose in Addition to Oral Sucrose Load

NCT ID: NCT02714413

Last Updated: 2017-07-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Individuals in the United States now consume a substantial proportion of their total energy as added sugars. The consumption of caloric sweeteners has been steadily increasing over the last four decades. The potential health consequences of this practice have been subject to considerable debate. In addition to weight gain, higher consumption of sugar-sweetened beverages is associated with development of metabolic syndrome and type 2 diabetes. These findings support the current dietary guidelines that encourage consumers to limit their intake of added sugars. There is a need for a sugar substitute that is safe, palatable and has favorable effects on energy metabolism and overall glucose homeostasis. One such sugar is possibly D-allulose also referred to in the literature as D-psicose. The present proposal is to address the efficacy of D-allulose in reducing postprandial blood glucose level in a random sample of Caucasian and African American population. Specifically the effect of D-allulose ingestion on the glucose and insulin response to a standardized oral glucose load will be studied.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Individuals in the United States now consume a substantial proportion of their total energy as added sugars. The consumption of caloric sweeteners has been steadily increasing over the last four decades. The potential health consequences of this practice have been subject to considerable debate. In a prospective follow-up study of 43,960 African American women who gave complete dietary and weight information and were free from diabetes at baseline, the incidence of type 2 diabetes mellitus was higher with higher intake of both sugar-sweetened soft drinks and fruit drinks. Similar conclusions were drawn in a meta- analysis of 11 studies of consumption of sugar-sweetened beverages in relation to risk of metabolic syndrome and type 2 diabetes. Thus, in addition to weight gain, higher consumption of sugar-sweetened beverages is associated with development of metabolic syndrome and type 2 diabetes. These findings support the current dietary guidelines that encourage consumers to limit their intake of added sugars. There is a need for a sugar substitute that is safe, palatable and has favorable effects on energy metabolism and overall glucose homeostasis. One such sugar is possibly D-allulose also referred to in the literature as D-psicose. D-allulose is a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Early clinical trials of D-allulose demonstrating its anti-diabetic and anti-obesity effects have been carried out in Kagawa (Japan). As of to date, there are still insufficient data to confirm the efficacy of pure D-allulose in Caucasian or African American populations. The present proposal is to address the efficacy of D-allulose in reducing postprandial blood glucose level in a random sample of Caucasian and African American population. This is a single center, prospective, randomized, double-blind, placebo-controlled crossover study evaluating the efficacy of pure D-allulose in Caucasian and African American populations. Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order on glycemic and insulin excursions associated with standardized oral sucrose load of 50 gms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Glucose

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

D-allulose Caucasian African American

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sucrose 50g + placebo

All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes

Group Type PLACEBO_COMPARATOR

sucrose

Intervention Type DIETARY_SUPPLEMENT

All subjects will receive a standardized oral sucrose load of 50 gms

Placebo

Intervention Type OTHER

Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.

Sucrose 50g + D-allulose 2.5 g

All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes

Group Type EXPERIMENTAL

D-allulose

Intervention Type DIETARY_SUPPLEMENT

Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.

sucrose

Intervention Type DIETARY_SUPPLEMENT

All subjects will receive a standardized oral sucrose load of 50 gms

Sucrose 50g + D-allulose 5.0 g

All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes

Group Type EXPERIMENTAL

D-allulose

Intervention Type DIETARY_SUPPLEMENT

Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.

sucrose

Intervention Type DIETARY_SUPPLEMENT

All subjects will receive a standardized oral sucrose load of 50 gms

Sucrose 50g + D-allulose 7.5 g

All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes

Group Type EXPERIMENTAL

D-allulose

Intervention Type DIETARY_SUPPLEMENT

Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.

sucrose

Intervention Type DIETARY_SUPPLEMENT

All subjects will receive a standardized oral sucrose load of 50 gms

Sucrose 50g + D-allulose10.0 g

All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes

Group Type EXPERIMENTAL

D-allulose

Intervention Type DIETARY_SUPPLEMENT

Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.

sucrose

Intervention Type DIETARY_SUPPLEMENT

All subjects will receive a standardized oral sucrose load of 50 gms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D-allulose

Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.

Intervention Type DIETARY_SUPPLEMENT

sucrose

All subjects will receive a standardized oral sucrose load of 50 gms

Intervention Type DIETARY_SUPPLEMENT

Placebo

Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

D-psicose

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women 18-70 years of age
* Have an HbA1C \< 5.8%.
* Subjects from whom informed consent has been obtained in accordance with University of Florida Institutional Review Board regulations.

Exclusion Criteria

* Pregnancy or lactation
* Diagnosed with diabetes mellitus
* Weight change ≥ 5 % within 3 months prior to admission to the study
* Has taken any weight loss medications within 3 months prior to admission to the study
* Immunocompromised status, including a debilitated state or malignancy
* Active liver, renal, thyroid diseases
* Frequent alcoholic consumption more than twice a week; with beer \> 360 mL, alcohol \> 45 mL, wine \> 150 mL for female, or beer \> 720 mL, whisky \> 90 mL, wine \> 300 mL for male each time
* Has gastrointestinal symptoms such as nausea, vomiting, loss of appetite, premature satiety, diarrhea, or chronic constipation
* Lack of ability or willingness to give informed consent
* Taken any medications than might cause weight loss or weight gain such as corticosteroid, antidepressant, antipsychotics, oral contraceptive pills \< 8 weeks or change the dose of these medication with 8 week prior to admission
* People with clinical diagnosis of diabetes.
* Patients in cardiac Class II, III or IV.
* Patients who have had renal transplants or are currently receiving renal dialysis.
* Patients with the diagnosis of psychosis.
* Patients with known HIV infection.
* Patients with history of malignancy within the last one year with the exception of localized skin cancers.
* Patients with significant clinical signs or symptoms of liver disease, acute or chronic hepatitis, or aspartate transaminase (AST or SGOT) greater than three times the upper reference range limit.
* Patients with clinical signs or symptoms of drug or alcohol abuse.
* Patients with a life expectancy of less than 5 years.
* Patients with any cognitive impairment diagnosed previously
* Patients with a serum creatinine greater 1.5 mg/dl.
* Patients exhibiting serious non-compliance with prescribed diet or drug therapy.
* Patients who are currently participating or have participated in a medical, surgical, or pharmaceutical investigation in which an investigational new drug was dispensed to the patient within the last 30 days months.
* Patients with a body mass index (B.M.I.) greater than 40 kg/m2.
* Patients with a body mass index (B.M.I.) less than 20 kg/m2.
* Any situation which precludes the patient from following and completing the protocol.
* Patients with known hemoglobinopathy or chronic anemia with hemoglobin \<10gm/dL.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dominick J Angiolillo, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Florida College of Medicine-Jacksonville

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Florida

Jacksonville, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Franchi F, Yaranov DM, Rollini F, Rivas A, Rivas Rios J, Been L, Tani Y, Tokuda M, Iida T, Hayashi N, Angiolillo DJ, Mooradian AD. Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study. BMJ Open Diabetes Res Care. 2021 Feb;9(1):e001939. doi: 10.1136/bmjdrc-2020-001939.

Reference Type DERIVED
PMID: 33637605 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IIS-Allulose-16

Identifier Type: -

Identifier Source: org_study_id